Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24489251 | 0.88 | NAAA (0.49) | DNM1TSHRALDH1A1NAAADGKA | |
| SCHEMBL15027504 | 0.85 | MGAM (0.41) | CHRNB2CHRNA4CHRM1TSHRALDH1A1 | |
| SCHEMBL24368308 | 0.79 | GPR88 (0.35) | CHRNB2CHRNA4TSHRALDH1A1CHRNB4 | |
| SCHEMBL10081285 | 0.79 | PRKCA (0.37) | CHRNB2CHRNA4TSHRALDH1A1CHRNB4 | |
| SCHEMBL19034578 | 0.78 | MAPT (0.36) | CHRNB2CHRNA4MAPT | |
| SCHEMBL23781853 | 0.78 | DNM1 (0.45) | DNM1ALDH1A1NAAADGKAMAPT | |
| SCHEMBL28134394 | 0.78 | DNM1 (0.45) | DNM1ALDH1A1NAAADGKAMAPT | |
| SCHEMBL8780794 | 0.78 | DNM1 (0.45) | DNM1ALDH1A1NAAADGKAMAPT | |
| SCHEMBL19242303 | 0.78 | CYP3A4 (0.45) | TSHRALDH1A1MAPK1 | |
| SCHEMBL10084981 | 0.77 | MEN1 (0.38) | TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | DNM1 472/4885CHRNB2 4172/4885CHRNA4 4242/4885 |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | DNM1 472/4885CHRNB2 4172/4885CHRNA4 4242/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | DNM1 472/4885CHRNB2 4172/4885CHRNA4 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.